Enovis (NYSE:ENOV) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Enovis to “buy” from “hold.” The broader analyst consensus is “Moderate Buy,” with 10 Buy, one Hold and one Sell rating and an average price target of $40.38.
• Enovis shares opened at $18.45, near their one-year low of $17.30 and well below the 50-day and 200-day moving averages of roughly $23.70. The company recently beat quarterly estimates, reporting $0.90 in EPS versus $0.85 expected and $582.78 million in revenue.
• Company insiders bought shares worth about $449,599 over the past 90 days, including purchases by the CEO and another insider. Institutional investors own 98.45% of Enovis’ outstanding stock.

Enovis (NYSE:ENOV - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Monday, Wall Street Zen reports.

A number of other brokerages also recently commented on ENOV. Citizens Jmp lowered their target price on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating for the company in a research note on Wednesday, September 2nd. UBS Group restated a "buy" rating and issued a $51.00 price target (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Wells Fargo & Company decreased their price target on Enovis from $39.00 to $33.00 and set an "overweight" rating for the company in a report on Wednesday, September 2nd. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings upgraded Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 21st. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.38.

Enovis Price Performance

ENOV stock opened at $18.45 on Monday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The firm has a market capitalization of $1.06 billion, a P/E ratio of -0.96 and a beta of 1.31. The business's 50-day moving average is $23.74 and its two-hundred day moving average is $23.65. Enovis has a 1 year low of $17.30 and a 1 year high of $34.28.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business's revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Enovis

In other news, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction dated Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, with a total value of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares of the company's stock, valued at approximately $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Oliver Engert bought 5,140 shares of Enovis stock in a transaction dated Thursday, September 3rd. The stock was purchased at an average cost of $19.46 per share, with a total value of $100,024.40. Following the completion of the acquisition, the insider directly owned 61,238 shares in the company, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 23,293 shares of company stock valued at $449,599 in the last 90 days. 2.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its holdings in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company's stock valued at $25,000 after acquiring an additional 1,174 shares during the period. Allworth Financial LP acquired a new position in shares of Enovis in the 2nd quarter valued at $36,000. Integrated Wealth Concepts LLC acquired a new position in shares of Enovis in the 2nd quarter valued at $39,000. Public Employees Retirement System of Ohio purchased a new stake in Enovis in the 2nd quarter valued at $48,000. Finally, Annis Gardner Whiting Capital Advisors LLC raised its position in Enovis by 468,400.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company's stock valued at $107,000 after purchasing an additional 4,684 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company's product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.